SILVER SPRING, Md., Feb. 25, 2013 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology and clinical stage provider of natural products and cell and gene therapy solutions for the treatment of diseases, discussed today additional reasons for its subsidiary, Medical Marijuana Sciences, Inc., to develop treatments for brain and pancreatic cancer that are based on cannabinoids from Cannabis sativa.
Plants have been the source of many well-known drugs for the treatment of a myriad of diseases, and cancer is no exception. For several years, the National Cancer Institute (NCI) in the U.S. has conducted a program that searches worldwide for new anticancer drugs from various natural sources, including plants. By using cannabinoids from Cannabis, such as cannabidiol, as the basis for developing treatments for deadly forms of cancer, Medical Marijuana Sciences, Inc. is, in fact, embracing the NCI's efforts.
There are many examples of cancer drugs from plants that are in widespread use throughout the world for a variety of cancers. Prominent among these are paclitaxel (Taxol®) from the bark of the Pacific yew tree (Taxus brevifolia), vincristine (Oncovin®) and vinblastine (Velban®) from the periwinkle plant and their synthetic derivatives vindesine (Eldisine®) and vinorelbine (Navelbine®), and Camptothecin™ from the bark and stem of the small Camptotheca acuminata tree native to China and Tibet. Derivatives of Camptothecin™ that are used in cancer treatment include topotecan (Hycantin®) and irinotecan (Camptosar®).
Typically, plant-derived drugs are used alone or with other drugs in combination chemotherapy treatment regimens. Some of these drugs are targeted to the treatment of one or two forms of cancer, while others are used to treat several forms of the disease. Furthermore, these naturally-occurring drugs have inspired the production of derivatives that are also used for cancer treatment.
Nuvilex's COO, Dr. Gerald Crabtree stated "By using cannabinoids for the development of treatments for some of the deadliest forms of cancer, Medical Marijuana Sciences, Inc. is building upon the strong foundation of very important cancer drugs that have come from plants. Given the knowledge that has accumulated in the scientific literature over the past few years, we feel that cannabinoids represent an excellent opportunity for the development of such treatments."
Dr. Robert Ryan, President and CEO of Nuvilex commented, "We are excited by the prospect that Nuvilex, through its new subsidiary Medical Marijuana Sciences, can contribute to the already strong arsenal of plant-derived anticancer agents."
Nuvilex, Inc. (OTCQB:NVLX) has been a provider of all-natural products for many years. The company has been expanded to increase its natural product-based footprint through medical marijuana studies. We are an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for research and medicine. New developments by our company and subsidiaries will be substantial as we have been working on many fronts to move us forward. Our company's offerings will ultimately include cancer, diabetes and other treatments using the Company's natural product knowledge, product base, cell and gene therapy expertise, and live-cell encapsulation technology in addition to other new products currently under development.
The Nuvilex, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13494
Safe Harbor Statement
This press release contains forward-looking statements described within the 1995 Private Securities Litigation Reform Act involving risks and uncertainties including product demand, market competition, and meeting current or future plans which may cause actual results, events, and performances, expressed or implied, to vary and/or differ from those contemplated or predicted. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, reflect events or circumstances afterward, or disclose unanticipated occurrences, except as required under applicable laws.
CONTACT: Investor Relations Contact: Marlin Molinaro Marmel Communications, LLC Ph: (702) 434-8692 firstname.lastname@example.org